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Abstract
Background: Numerous studies on publication bias in clinical drug research have been undertaken, particularly on
the association between sponsorship and favourable outcomes. However, no standardized methodology for the
classification of outcomes and sponsorship has been described. Dissimilarities and ambiguities in this assessment
impede the ability to compare and summarize results of studies on publication bias. To guide authors undertaking
such studies, this paper provides recommendations for a uniform assessment of publication bias related to funding
source.
Methods and results: As part of ongoing research into publication bias, 472 manuscripts on randomised
controlled trials (RCTs) with drugs, submitted to eight medical journals from January 2010 through April 2012, were
reviewed. Information on trial results and sponsorship was extracted from manuscripts. During the start of this
evaluation, several problems related to the classification of outcomes, inclusion of post-hoc analyses and follow-up
studies of RCTs in the study sample, and assessment of the role of the funding source were encountered. A
comprehensive list of recommendations addressing these problems was composed. To assess internal validity,
reliability and usability of these recommendations were tested through evaluation of manuscripts submitted to
journals included in our study.
Conclusions: The proposed recommendations represent a first step towards a uniform method of classifying trial
outcomes and sponsorship. This is essential to draw valid conclusions on the role of the funding source in
publication bias and will ensure consistency across future studies.
Keywords: Publication bias, Clinical drug research, Sponsorship, Pharmaceutical industry, Trial outcomes,
Recommendations, Uniform assessment
Background
Introduction
In recent years, the issue of publication bias in clinical
drug research has been widely addressed. Studies re-
porting results that are positive or favourable to the ex-
perimental drug are more likely to be published, and
outcomes that are statistically significant have higher
odds of being fully reported [1-3]. Funding by the
pharmaceutical industry and financial conflicts of inte-
rest among authors have particularly been associated
with publication of favourable outcomes [4-6]. Publication
bias could result from researchers and sponsors failing to
submit trials with negative results, or from favouritism
towards publication of positive results among peer re-
viewers, journal editors and publishers.
Numerous studies on the association between spon-
sorship and trial outcomes have been undertaken [6].
Classification of outcomes as positive or negative and
establishing the role of the funding source may appear
to be straightforward. However, when reviewing studies
on publication bias, no standardized methodology for
the assessment of outcomes and sponsorship has been
described. Definitions used for classification of trial out-
comes are inconsistent across studies and the terms
‘sponsored by industry’ and ‘conflict of interest’ have
been applied in different ways.
In a majority of the studies on publication bias, methods
for classification of trial outcomes are only reported to a
very limited extent, though there are positive exceptions
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[5,7]. However, this assessment is not without hurdles, for
instance when reviewing results of non-inferiority or
equivalence trials and trials reporting safety rather than ef-
ficacy outcomes. Some studies concentrate on results
reported for primary endpoints, while others examine
conclusion sections to classify outcomes. Some investiga-
tors briefly mention that included trials are categorized
according to funding source [7-9], while in other papers
explicit criteria are given for the classification based on
sponsor type. Drug trials are often considered to be
industry-sponsored when funded by a pharmaceutical
company [6,10-12], while some researchers also regard
donation of study medication by a manufacturer as
industry-sponsorship [6,10,11,13]. In addition, drug
trials are sometimes classified as industry-sponsored if
authored by one or more employees of the company
manufacturing the test drug [10,11,13,14]. Further-
more, the terms industry-funded, industry-supported,
and industry-sponsored are used interchangeably when
categorizing trials according to sponsorship.
Dissimilarities and ambiguities in the classification of
outcomes and sponsorship impede the ability to com-
pare and summarize results of studies on publication
bias. A standardized approach, taking into account dif-
ferent types of financial and material support and a clear
definition of trial outcomes, is essential to draw valid
conclusions on the role of the funding source in publica-
tion bias. To guide authors undertaking studies on the
association between sponsorship and study outcomes or
authors undertaking systematic reviews or meta-analyses
of such studies, this paper provides recommendations
for a uniform assessment of publication bias related to
funding source.
Methods
As part of ongoing research into biased reporting of trial
outcomes, we assessed the role of editorial and peer
review processes in publication bias. We evaluated whe-
ther submitted manuscripts with negative outcomes
were less likely to be published than studies with positive
outcomes, and determined the influence of sponsorship
in this context. We retrospectively reviewed manuscripts
submitted to eight journals from January 2010 through
April 2012. One general medical journal (British Medical
Journal) and seven specialty journals (Annals of the
Rheumatic Diseases, British Journal of Ophthalmology,
Diabetologia, Gut, Heart, Journal of Hepatology, and
Thorax) were included. Journals were selected based on
impact factor (journals indexed with the highest impact
factors within subject categories, according to Institute
for Scientific Information Journal Citation Report 2011),
and the number of drug RCTs published in 2010–2011.
Manuscripts reporting results of RCTs were included, if
at least one study arm assessed the efficacy or safety of a
drug intervention and a statistical test was used to evalu-
ate treatment effects (n = 472). Two authors (MvL, HJO)
extracted information on trial results and financial or
material support from manuscripts.
During the start of this evaluation, we encountered
several problems related to (1) the classification of out-
comes, (2) inclusion of post-hoc and subgroup analyses
and follow-up studies of RCTs in the study sample, and
(3) assessment of the role of the funding source. These
problems hampered unequivocal judgment on sponsor-
ship and the direction of trial outcomes. We composed
a list of recommendations addressing these problems, to
facilitate a standardized assessment of manuscripts in-
cluded in our study and future studies on publication bias.
To assess internal validity, reliability and usability of the
recommendations were tested through evaluation of ma-
nuscripts submitted to journals included in our study.
Minor adjustments were made during this process, and a
comprehensive list of recommendations was created.
Findings
Identified problems
Classification of trial outcomes
Poorly described methodology and lack of (or multiple)
primary endpoints A poor description of trial design in
research papers complicates the selection of manuscripts
that are eligible for inclusion when conducting a study
on publication bias. As trial outcomes are often clas-
sified based on results for reported primary endpoints,
failure to accurately define a primary endpoint among a
plurality of outcomes described or mentioning multiple
primary endpoints constitutes a problem. Guidelines for
accurate reporting of RCTs are available by means of the
CONSORT Statement (Consolidated Standards of Re-
porting Trials) [15], but the quality of reporting regarding
these and other aspects remains sub-optimal after publi-
cation of CONSORT recommendations [16,17].
Safety as primary endpoint An issue not related to the
adequacy of reporting, but to the type of outcomes
reported, is represented by trials with safety rather than ef-
ficacy as a primary endpoint. It could be argued whether
trial results should be classified as positive when the test
drug is proven to be as safe as the control treatment, or
whether this would only be valid when less adverse events
are reported for the test drug than for the comparator.
Furthermore, it can be difficult to determine whether
reported outcomes should be considered as efficacy or
safety endpoints.
Non-inferiority and equivalence trials Problems re-
lated to trial design also apply to outcomes of non-
inferiority and equivalence trials. In case non-inferiority
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or equivalence is established for treatments in these
trials, outcomes could be considered positive, as they
confirm the hypothesis of the trial. However, there are
no clinically relevant differences between treatments
with regard to the primary outcome of the trial, which
could also be interpreted as a negative finding.
Inclusion of post-hoc analyses and follow-up studies of trials
It could be argued whether post-hoc and subgroup ana-
lyses and follow-up studies of RCTs should be included
in studies on publication bias, next to original trial re-
ports. Due to inadequate reporting on methodological
aspects as described above, it can be difficult to discri-
minate between original reports and secondary analyses
of trial data based on publications in the scientific litera-
ture. Unless original trial protocols are available, it is
often not possible with a high degree of certainty to
make judgments on what is post-hoc and what is not.
However, post-hoc and subgroup analyses and follow-up
studies of RCTs could be equally prone to influences of
sponsorship and direction of results on publication of
studies.
Role of the funding source
Different levels of support Assessment of the role of
the funding source in drug trials is complex because of
the variety of levels of involvement reported, ranging
from financial support and donation of study medication
by a pharmaceutical company, to input of the manufac-
turer in the trial design, conduct, data analysis and pub-
lication of results. Financial support from industry is
often described as unrestricted educational grants, which
suggests that funding was given without any predefined
involvement of the funder. Furthermore, some trials are
authored by one or more employees of the company
manufacturing the test drug or funding the study.
Inadequate reporting of sponsorship The assessment
of sponsorship can be complicated by the fact that some
journals do not report funding sources or do not explain
the sponsor’s role in a trial, and authors may not dis-
close received funding. Consequently, trials receiving
industry funding could be falsely classified as non-
industry. The CONSORT 2010 Statement and the Uni-
form Requirements for Manuscripts Submitted to Bio-
medical Journals of the International Committee of
Medical Journal Editors (ICMJE) [15,18], both adopted
by many journals, insist on reporting of information on
funding sources and other support and the role of
funders. However, not all authors adhere to these guide-
lines when submitting manuscripts, and even if authors
do adhere to them, journal editors may not require the
material to be reported.
Formal sponsorship It is often unclear based on the in-
formation reported in manuscripts whether trials should
be regarded as investigator-initiated studies or that phar-
maceutical companies qualify for formal sponsorship as
defined in the ICH-GCP (International Conference on
Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use – Good Clinical
Practice) guidelines [19]. According to these guidelines,
a study sponsor is “an individual, company, institution,
or organization which takes responsibility for the initi-
ation, management, and/or financing of a clinical trial.”
Therefore, financial support only does not necessarily
imply formal sponsorship by the donor. In the public
trial registries ClinicalTrials.gov, EU Clinical Trials
Register and ISRCTN Register, definitions for funding
and sponsorship are not consistent across registries and
do not unequivocally discriminate between trials for-
mally sponsored by industry according to ICH-GCP
guidelines, and those receiving only financial or material
support.
Non-profit trials When absence of industry support is
evident, it can subsequently be difficult to distinguish
between trials sponsored by governmental sources ver-
sus other nonprofit organisations. Frequently, it is un-
clear which party carries responsibility regarding quality
and safety measures during trials. Furthermore, trials
can be supported by non-industry organisations, that are
owned by pharmaceutical companies.
Recommendations
Classification of trial outcomes
Outcomes of drug RCTs should be classified as positive
if results for the primary endpoint (as reported) are sta-
tistically significant (p < 0.05 or 95% confidence interval
[CI] for difference excluding 0 or 95% CI for ratio ex-
cluding 1) and supports the efficacy of the test drug; or
negative if the result does not reach statistical signifi-
cance or is statistically significant in the direction of the
control treatment being more efficacious (Table 1).
When a trial is designed as an equivalence or non infer-
iority study and the two treatments are equivalent, i.e.
differences in treatment effects do not equal or exceed
preset margins, results should be classified as positive.
When treatments are equally effective regarding the pri-
mary endpoint and it is not clearly stated whether a trial
was designed as superiority or non-inferiority trial,
results should be classified as positive. For manuscripts
describing a safety parameter as primary endpoint, trials
in which the test drug is reported to be as safe or safer
than the control treatment (either placebo or active
comparator) should be considered as positive. When
authors explicitly hypothesized that the test drug is
expected to be less harmful than control, only trials
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reporting results that support the safety of the test drug
should be classified as positive. If treatments are equally
harmful, results should be classified as negative.
If no primary outcome is stated for a trial, or multiple
primary endpoints are selected, results should be clas-
sified based on the statistical significance and direction
of most (primary) outcomes (>50%). When two co-
primary outcomes are stated, results for both endpoints
should support the efficacy or safety of the test drug in
order to classify a trial as positive. If results for only one
of the two endpoints are statistically significant in favour
of the test drug, results should be classified as negative.
When treatment effects are not directly compared bet-
ween groups in the statistical analysis (i.e. against base-
line measurements in each treatment arm), results
should be classified as positive if they are statistically sig-
nificant in favour of the test drug. If uncertainty remains
over the classification of trial outcomes, studies should
be scored as negative, unless the overall tone of the con-
clusion section favours the test drug.
Inclusion of post-hoc analyses and follow-up studies of trials
Studies explicitly referred to as post-hoc or subgroup
analyses and follow-up studies of single RCTs are eligible
for inclusion in studies on publication bias, if they com-
pare the efficacy or safety of treatments to which parti-
cipants have been assigned in an RCT, but with regard
to other (secondary) outcomes, limited to a specific part
of the original study population, or with an extended
follow-up in these analyses. Post-hoc and subgroup ana-
lyses based on combined data of multiple RCTs should
not be included.
Role of the funding source
Drug trials should be considered as non-industry studies
when no associations with a pharmaceutical company
can be identified in the trial manuscript. No author-
industry affiliations are reported, no manufacturer is
named in the materials and methods section or acknow-
ledgements for providing study medication or placebos
free of charge, and no statements are made about finan-
cial support from pharmaceutical companies (Table 2).
These RCTs are sponsored by governmental or other
non-profit organizations, including universities, hospitals
and foundations.
Trials should be classified as industry-sponsored when a
pharmaceutical company is explicitly described as study
sponsor in the manuscript, or when the company funding
the trial is reported to have participated in the study de-
sign, data collection, analysis, preparation of the manu-
script, and/or decision to publish. Involvement of authors
employed by a pharmaceutical company is indicative of
industry sponsorship, but not sufficient to qualify a trial as
industry-sponsored. Studies reporting donation of study
medication or receipt of financial support from a pharma-
ceutical company, and trials with one or more authors
employed by the company manufacturing the test drug
should be assigned to a separate class of industry-sup-
ported trials. Sole provision of grants or drugs does not
fully comply with criteria for sponsorship according to
ICH-GCP guidelines, and thus differs from formal spon-
sorship by a pharmaceutical company. However, when a
trial is funded by industry and there are company-
employed co-authors, the company will likely participate
in the conduct and reporting of the trial. These trials
should be classified as industry-sponsored, if the role of
the funding source is not explicitly reported. Trials funded
or otherwise supported by a nonprofit organisation owned
by a pharmaceutical company should be categorized as in-
dustry-supported. Investigator-initiated post-hoc analyses
of single RCTs that were formally sponsored by industry
should also be scored as industry-supported. When doubt
remains over sponsorship and the trial is registered, infor-
mation in the trial registry should take precedence over
other sources of information.
Table 1 Classification of outcomes of drug RCTs based on
results reported for primary endpoints
Positive
outcome
Negative
outcome
Results for primary endpoint statistically
significant and supporting the efficacy of test
drug
X
Results for primary endpoint do not reach
statistical significance
X
Results for primary endpoint statistically
significant in direction of control treatment
being more efficacious
X
Treatments equivalent regarding primary
endpoint in non-inferiority or equivalence trials
X
Treatments equally effective regarding primary
endpoint in trials not explicitly described as
superiority or non-inferiority study
X
Test drug as safe or safer than control treatment
in trials with safety parameter as primary
endpoint
X
Treatments equally harmful in trials with safety
parameter as primary endpoint, when
hypothesized that test drug is expected to be
safer than control
X
Results for >50% of (primary) endpoints
statistically significant in favour of test drug,
when no/multiple primary endpoints are
reported
X
Results for one primary endpoint statistically
significant in favour of test drug, when two
co-primary endpoints are reported
X
Treatment effects not compared between
groups but against baseline in each arm; results
for primary endpoint statistically significant in
favour of test drug
X
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Discussion
In this study, several problems related to the classification
of outcomes and sponsorship were identified. We have
formulated recommendations addressing these problems
to facilitate a uniform assessment of manuscripts included
in studies on publication bias.
In this article, we have focused on the assessment of
publication bias related to funding source. However, the
relationship between favourable outcomes and spon-
sorship is much more complex. Numerous systematic re-
views have found that industry sponsorship is associated
with results that are favourable to the product of the com-
pany funding the trial [4,20,21]. Besides publication bias,
there are other ways by which outcomes may be
influenced. Industry bias may occur through the choice of
comparators, dosing and timing of comparisons, coding of
events and selective data analysis, interpretation of data
and selective outcome reporting [6,21,22]. Although we
have concentrated on publication bias, our recommenda-
tions are generally applicable to studies comparing indus-
try versus non-industry trials in relation to favourable
outcomes. Furthermore, we only considered drug RCTs,
but the recommendations are equally relevant to device
studies, as these are also often sponsored by companies
with a financial interest in the study outcomes.
In our recommendations, reported results are classi-
fied as positive or negative. Trials in which primary end-
points are reached or study hypotheses are confirmed
are considered to be positive. Possible alternatives to
categorize trials would include ‘significant’ vs ‘non-sig-
nificant’, or ‘favorable’ vs ‘unfavorable’ findings. However,
use of these terms would impede the classification of
non-inferiority or equivalence trials and studies with
safety parameters as the primary endpoint. We have not
included a third ‘neutral’ category, as we aimed to keep
the classification as straightforward as possible. More-
over, previous studies on publication bias found rela-
tively low numbers of studies with neutral or unclear
results [23-25], so we included these in the ‘negative’
category.
For the classification of outcomes, we have concen-
trated on results reported for the primary endpoint.
However, in several studies on industry bias, trials are
categorized as positive if the conclusion is favourable
(i.e. the authors recommend the test drug), not the
reported results [13]. In this article, we recommend con-
sidering conclusions only when trials cannot be classified
based on reported results. Previous studies reporting on
concordance between study results and conclusions
found that industry-sponsored trials were less concor-
dant than non-industry studies [6]. This lack of concor-
dance, and the finding that industry-sponsored studies
are more likely to have favourable conclusions [6], may
be explained by the use of distorted presentation or
‘spin’ in papers [26]. As results may be more objective
measures of treatment effects, we chose to concentrate
on the assessment of results. Future studies on publi-
cation bias should clearly state whether trial results or
conclusions are being examined.
Trials were classified as non-industry, industry-sup-
ported or industry-sponsored. One of the most fun-
damental differences between industry-supported and
Table 2 Classification of drug RCTs according to sponsor type
Non-industry trial Industry-supported
trial
Industry-sponsored
trial
1. Pharmaceutical company explicitly reported as study sponsor in
manuscript
X
2. Company funding the trial participated in design, conduct,
analysis, writing of article and/or decision to publish
X
3. Trial funded by industry and author(s) affiliated to industry, but
role of funding source not reported
X
4. Financial support received from pharmaceutical company X
5. Donation of study medication or placebos by manufacturer X
6. One or more authors employed by pharmaceutical company
manufacturing the test drug
X
7. Trial supported by nonprofit organisation owned by
pharmaceutical company
X
8. Investigator-initiated post-hoc analysis of single RCT formally
sponsored by industry
X
9. Pharmaceutical industry not in any way involved in trial X
Formal study sponsor according to ICH-GCP guidelines Nonprofit
organisation
Nonprofit organisation Pharmaceutical company
Responsible party for quality and safety measures during trial Nonprofit
organisation
Nonprofit organisation Pharmaceutical company
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industry-sponsored studies relates to the overall responsi-
bility for the conduct of the trial as defined by ICH-GCP
guidelines. Industry-supported trials are done under the
responsibility of non-profit organizations in contrast to
industry-sponsored studies. This distinction is usually not
made in previous literature but is very relevant in terms of
quality assessment of reported research. We have not
included a category of ‘sponsorship not stated’. Many
journals nowadays ask for information on received fun-
ding and the role of the funding source, and require that
manuscripts on RCTs conform to ICMJE requirements
and CONSORT guidelines. Therefore, most trials recently
submitted should report on funding and be registered in a
trial registry, making information on sponsorship trace-
able. However, the non-industry category may include tri-
als that received industry support, if authors failed to
disclose funding. In a recent Cochrane review on sponsor-
ship and research outcomes, studies were also coded as
non-industry if it was not reported who sponsored the
study. The review authors stated that some of these trials
were likely industry-sponsored, but no changes in results
were seen when studies without sponsorship statements
were excluded [6]. In addition, industry-sponsored studies
may be misclassified as industry-supported, as apparently
independently conducted industry-supported trials may
have unreported sponsor involvement [27].
For future studies on publication bias, it is important
that the quality of reporting on design and sponsorship
of trials is improved. Journals should actively enforce the
CONSORT Statement and ICMJE requirements, and
could require authors to complete a form for disclosure
of sponsorship and support received for the reported
trial [28].
We emphasize that our recommendations are only vali-
dated for use by three investigators. In order to prove
whether the recommendations are acceptable to re-
searchers in general, it is essential that the external validity
of this proposed classification system is determined in a
study undertaken by different researchers on a different
sample of manuscripts. To establish external validity, a
Delphi consensus technique could be conducted among a
larger group of researchers. Future research should focus
on whether the classification system is adopted in practice
by investigators undertaking studies on trial outcomes and
sponsorship.
In conclusion, the recommendations proposed in this
article represent a first step towards a uniform method of
classifying trial outcomes and sponsorship. This is essen-
tial to draw valid conclusions on the role of the funding
source in publication bias and will ensure consistency
across future studies.
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